JPRN-jRCT2080221112未知3 期
A multicenter, double-blind, randomized, dose-comparison study of three different doses of aripiprazole orally administered over 6 weeks in pediatric patients with schizophrenia
适应症
试验速览
- 阶段
- 3 期
- 入组人数
- 99
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 13age old 至 <= 17age old（—）
- 性别
- All
入选标准
- •1) Patients with a diagnosis of schizophrenia according to DSM-IV-TR
- •2) Male and female patients aged 13-17 years
- •3) Inpatient or outpatient status
排除标准
- •1) Patients who have a diagnosis of any other disease except schizophrenia according to DSM-IV-TR
- •2) Patients who fall under a contraindication listed in the ABILIFY package insert
研究者
相似试验
已完成
2 期
A multi-center, randomized, double-blind, dose-parallel, placebo-controlled phase II clinical trial to evaluate the effectiveness and safety of Ganmao Shuangjie Granules in the treatment of influenza (external cold, internal heat syndrome)influenza (external cold, internal heat syndromeITMCTR2100005067Beijing Hospital of Traditional Chinese Medicine
招募中
2 期
A multi-center, randomized, double-blind, dose exploration, placebo parallel controlled phase II clinical trial to evaluate the efficacy and safety of Yuping Tongqiao Tablets in the treatment of persistent allergic rhinitis (deficiency of lung and spleen)Persistent allergic rhinitisITMCTR2100004325Beijing Hospital of Traditional Chinese Medicine
进行中（未招募）
不适用
A Randomized, Double-blinded, Multicenter, Dose and Duration Finding Study to Evaluate the Sustained Virologic Response of the HCV Polymerase Inhibitor Prodrug (RO5024048) in Combination with Pegasys and Copegus versus the Currently Approved Combination of Pegasys and Copegus in Treatment-Naive Patients with Chronic Hepatitis C Genotype 1 or 4 Virus Infection. - NDChronic Hepatitis C (CHC) Genotype 1 or 4MedDRA version: 12.1Level: LLTClassification code 10008912Term: Chronic hepatitis CEUCTR2008-008258-21-ITF. Hoffmann - La Roche Ltd - Pharmaceutical Division, PDR400
进行中（未招募）
1 期
A Randomized, Double-blinded, Multicenter, Dose and Duration Finding Study to Evaluate the Sustained Virologic Response of the HCV Polymerase Inhibitor Prodrug (RO5024048) in Combination with Pegasys® and Copegus® versus the Currently Approved Combination of Pegasys® and Copegus® in Treatment-Naive Patients with Chronic Hepatitis C Genotype 1 or 4 Virus Infection.EUCTR2008-008258-21-GBF. Hoffmann-La Roche Ltd400
进行中（未招募）
不适用
A Randomized, Double-blinded, Multicenter, Dose and Duration Finding Study to Evaluate the Sustained Virologic Response of the HCV Polymerase Inhibitor Prodrug (RO5024048) in Combination with Pegasys® and Copegus® versus the Currently Approved Combination of Pegasys® and Copegus® in Treatment-Naive Patients with Chronic Hepatitis C Genotype 1 or 4 Virus Infection.Chronic Hepatitis CMedDRA version: 9.1Level: LLTClassification code 10008912Term: Chronic hepatitis CEUCTR2008-008258-21-DEF. Hoffmann-La Roche Ltd400